Trials / Completed
CompletedNCT03389126
Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label, single arm, Phase II study of avelumab in patients with advanced hepatocellular carcinoma after prior sorafenib treatment
Detailed description
This is an open label study of avelumab monotherapy. Patients with advanced hepatocellular carcinoma after prior sorafenib treatment are eligible. Patients should have failed to sorafenib or be intolerant to sorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2019-12-31
- Completion
- 2020-01-31
- First posted
- 2018-01-03
- Last updated
- 2021-03-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03389126. Inclusion in this directory is not an endorsement.